Astellas and Pfizer Reached Settlement on Declaratory Judgment Action Relating to Lipitor Agreement.Tokyo, Japan, Jan 26, 2007 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) Newswire) - Pfizer Japan Inc. and Astellas Pharma Astellas Pharma Inc. (アステラス製薬株式会社 Inc. announced that a settlement has been reached today by Pfizer, Pfizer's affiliate, and Astellas, which are the parties to a Development and Marketing Agreement for a hypercholesterolemia Hypercholesterolemia Definition Hypercholesterolemia refers to levels of cholesterol in the blood that are higher than normal. Description Cholesterol circulates in the blood stream. It is an essential molecule for the human body. drug "Lipitor(R)" manufactured and distributed by Astellas and promoted jointly by Pfizer and Astellas in Japan (the "DMA (1) (Digital Media Adapter) See digital media hub. (2) (Document Management Alliance) A specification that provides a common interface for accessing and searching document databases. ") on a declaratory judgment declaratory judgment In law, a judgment merely declaring a right or establishing the legal status or interpretation of a law or instrument. It is binding but is distinguished from other judgments or court opinions in that it includes no executive element (an order that action filed by Astellas to confirm that the term of DMA shall continue until July 8, 2016. The action was filed by Astellas on November 7, 2006 at the Tokyo District Court Tokyo District Court (東京地方裁判所; Tōkyō Chihō Saibansho) is a district court in Kasumigaseki, Chiyoda, Tokyo, Japan. See also
The settlement agreement contains the following conditions: - The DMA is amended a·mend v. a·mend·ed, a·mend·ing, a·mends v.tr. 1. To change for the better; improve: amended the earlier proposal so as to make it more comprehensive. 2. to the effect that the term of DMA will expire on July 8, 2016. - All other terms and conditions of the DMA will remain unchanged. - Astellas will withdraw the declaratory judgment action. The settlement involves no payment from either party to the other. Pfizer and Astellas are pleased with the prompt resolution of this issue, and are committed to the marketing and promotion of Lipitor in Japan with a renewed focus. About Astellas Pharma Inc. Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. In April 2005, the company was formed through the merger of Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. The organization is committed to becoming a global mega pharmaceutical company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. For more information on Astellas Pharma Inc., please visit the company's website at www.astellas.com. Source: Astellas Pharma Inc. Contact: Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com Pfizer Japan Inc. Corporate Communications Tel: +81-3-5309-7201 Fax: +81-3-5309-9004 http://www.pfizer.co.jp Copyright [c] 2007 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion